In an earlier BRAINSTORMS, 1 the secondary binding characteristics of the SSRIs were examined. Here we show these graphically for all 5 agents (fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram). We also propose how such properties can create potential advantages and disadvantages for various patient profiles.
2 Understanding not only the primary action of the SSRIs (namely, serotonin reuptake inhibition) but also how each of the 5 SSRIs differs from one another in the dozen or so secondary pharmacologic actions may assist the prescriber in selecting a specific SSRI to match the clinical profile of an individual patient. At best, these are rules for which there are many exceptions when applied to an individual patient.
Matching Each SSRI's Secondary Binding Properties With Patient Profiles
Abbreviations: CYP = cytochrome P450 1A2, 2D6, or 3A4 inhibitor, DRI = dopamine reuptake inhibitor, 5-HT 2C = sertonin 2C agonist, GI = gastrointestinal, m-ACh = muscarinic cholinergic antagonist, NOS = nitric oxide synthase inhibitor, NRI = norepinephrine reuptake inhibitor, σ = sigma, OCD = obsessive-compulsive disorder, SRI = serotonin reuptake inhibitor. 
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